Zynerba stock soars after getting 'fast track' designation for experimental cannibanoid therapy
Zynerba stock soars after getting 'fast
track' designation for experimental cannibanoid therapy
Th FDA awarded the fast track designation to a product the Main Line company is developing to treat patients with Fragile X Syndrome.
Story continues